Eli Lilly and Company (LLY) is Attracting Investor Attention: Here is What You Should Know

Eli Lilly (LLY) is experiencing increased investor attention, with shares up 9.8% in the past month, outperforming the S&P 500 and its industry. Current quarter earnings are projected at $5.56 per share, a 41.8% year-over-year increase, and revenue is estimated at $14.47 billion, up 28% year-over-year; however, the stock holds a Zacks Rank #3, suggesting near-term performance in line with the broader market.

Analysis

Eli Lilly (LLY) has demonstrated notable investor interest, with its shares delivering a +9.8% return over the past month, significantly outpacing the Zacks S&P 500 composite's +0.5% change and the Zacks Large Cap Pharmaceuticals industry's +2.7% gain. The company's earnings are projected to reach $5.56 per share for the current quarter, marking a substantial +41.8% year-over-year increase, with the Zacks Consensus Estimate for this period experiencing a +0.5% upward revision in the last 30 days. For the current fiscal year, the consensus earnings estimate stands at $21.95, indicating a +69% growth from the prior year, although this estimate has seen a slight -0.6% downward adjustment over the last 30 days. Looking ahead, the consensus earnings estimate for the next fiscal year is $30.91, representing a +40.8% year-over-year increase, with this estimate having been revised upwards by +0.3% in the past month. Revenue projections are also strong: consensus sales estimates are $14.47 billion for the current quarter (+28% YoY), $59.92 billion for the current fiscal year (+33% YoY), and $72.43 billion for the next fiscal year (+20.9% YoY). In its most recent reported quarter, Lilly's revenues were $12.73 billion, a +45.2% year-over-year increase and a +0.86% surprise; however, its EPS of $3.34 was a -5.11% surprise compared to estimates. Despite these robust growth figures, Lilly carries a Zacks Rank #3 (Hold), suggesting its near-term stock performance may align with the broader market. The company's valuation, as indicated by a Zacks Value Style Score of C, implies it is trading at par with its peers.

Key Decisions for Investors

• Investors should weigh Eli Lilly's strong projected multi-year earnings and revenue growth, and its recent market outperformance, against the current Zacks Rank #3 (Hold) which suggests near-term performance in line with the broader market.
• It is advisable to monitor upcoming earnings reports closely, particularly given the -5.11% EPS surprise in the last reported quarter despite a revenue beat, and the mixed recent revisions to current fiscal year earnings estimates.
• Considering the stock's valuation is at par with peers (Zacks Value Style Score C), investors should assess if the significant growth prospects are adequately balanced with the current market price and the neutral near-term outlook.